Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Expanded Access Program of SER-109 in patients with multiple recurrent Clostridium difficile infection (CDI)

Trial Profile

An Expanded Access Program of SER-109 in patients with multiple recurrent Clostridium difficile infection (CDI)

Status: Recruiting
Phase of Trial: Clinical Phase Unknown

Latest Information Update: 02 Apr 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs SER 109 (Primary)
  • Indications Clostridium difficile infections
  • Focus Expanded access; Therapeutic Use
  • Most Recent Events

    • 30 Mar 2020 According to a Seres Therapeutics media release, the company plans to initiate a SER-109 Expanded Access Program at selected clinical sites participating in the ongoing Phase 3 ECOSPOR III study, and the Company may also initiate the program at additional clinical sites for eligible patients to have access to SER-109.
    • 16 May 2016 According to a Seres Therapeutics media release, company has initiated expanded access program at selected sites participating in the ongoing Phase 2 study
    • 05 May 2016 New trial record

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top